New Leadership at 23andMe: Can the Company Turn Things Around?
Genetic-testing company 23andMe has appointed three new independent directors to its board, just a month after all seven of its previous directors abruptly resigned. The move is seen as a significant step in the company’s efforts to revamp its leadership and turn its fortunes around.
Meet the New Board Members
The new directors are Andre Fernandez, former CFO of WeWork; Jim Frankola, former CFO of Cloudera; and Mark Jensen, a tech advisor and former managing partner at Deloitte. They will join 23andMe’s co-founder and CEO Anne Wojcicki on the board, with Jensen serving as lead independent director and chair of the compensation committee.
A Fresh Start?
Wojcicki expressed enthusiasm for the new appointments, stating that she looks forward to working with the experienced directors. However, the company’s recent history suggests that there are significant challenges ahead. 23andMe has struggled since going public in 2021, with shares plummeting to below $1 before a recent reverse stock split.
A Disagreement Over Direction
The previous independent directors resigned in September, citing disagreements with Wojcicki over the company’s strategic direction. Despite efforts to explore potential paths forward, including a special committee formed in March, the directors ultimately rejected Wojcicki’s proposal to take the company private.
What’s Next?
With the new board members in place, 23andMe may be poised for a fresh start. However, the company’s future remains uncertain, and it remains to be seen whether the new leadership can help turn things around.
A Commitment to Going Private
Wojcicki has repeatedly stated her commitment to taking the company private, but the path forward is unclear. As the company navigates this critical juncture, investors and analysts will be watching closely to see what’s next for 23andMe.
Leave a Reply